Eric Zhou1, Aaron Lord2, Amelia Boehme3,4, Nils Henninger5,6, Adam de Havenon7, Farhaan Vahidy8, Koto Ishida2, Jose Torres2, Eva A Mistry9, Brian Mac Grory10, Kevin N Sheth11, M Edip Gurol12, Karen Furie10, Mitchell S V Elkind3,4, Shadi Yaghi2. 1. NYU Grossman School of Medicine, New York, NY (E.Z.). 2. Department of Neurology, NYU Langone Health, New York, NY (A.L., K.I., J.T., S.Y.). 3. Department of Neurology, Vagelos College of Physicians and Surgeons (A.B., M.S.V.E.), Columbia University, New York, NY. 4. Department of Epidemiology, Mailman School of Public Health (A.B., M.S.V.E.), Columbia University, New York, NY. 5. Department of Neurology, University of Massachusetts Medical Center, Worcester (N.H.). 6. Department of Psychiatry, University of Massachusetts, Worcester (N.H.). 7. Departments of Neurology, University of Utah Medical Center, Salt Lake City (A.d.H.). 8. Center for Outcomes Research, The Houston Methodist Neurological Institute, TX (F.V.). 9. Department of Neurology, Vanderbilt University Medical Center, Nashville, TN (E.A.M.). 10. Department of Neurology, Brown University, Providence, RI (B.M.G., K.F.). 11. Department of Neurology, Yale University, New Haven, CT (K.N.S.). 12. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.G.).
Abstract
BACKGROUND AND PURPOSE: Anticoagulation therapy not only reduces the risk of ischemic stroke in atrial fibrillation (AF) but also predisposes patients to hemorrhagic complications. There is limited knowledge on the risk of first-ever ischemic stroke in patients with AF after extracranial hemorrhage (ECH). METHODS: We conducted a retrospective study using the California State Inpatient Database including all nonfederal hospital admissions in California from 2005 to 2011. The exposure variable was hospitalization with a diagnosis of ECH with a previous diagnosis of AF. The outcome variable was a subsequent hospitalization with acute ischemic stroke. We excluded patients with stroke before or at the time of ECH diagnosis. We calculated adjusted hazard ratios for ischemic stroke during follow-up and at 6-month intervals using Cox regression models adjusted for pertinent demographics and comorbidities. In subgroup analyses, subjects were stratified by primary ECH diagnosis, severity/type of ECH, age, CHA2DS2-VASc score, or the presence/absence of a gastrointestinal or genitourinary cancer. RESULTS: We identified 764 257 patients with AF (mean age 75 years, 49% women) without a documented history of stroke. Of these, 98 647 (13%) had an ECH-associated hospitalization, and 22 748 patients (3%) developed an ischemic stroke during the study period. Compared to patients without ECH, subjects with ECH had ≈15% higher rate of ischemic stroke (overall adjusted hazard ratio, 1.15 [95% CI, 1.11-1.19]). The risk appeared to remain elevated for at least 18 months after the index ECH. In subgroup analyses, the risk was highest in subjects with a primary admission diagnosis of ECH, severe ECH, gastrointestinal-type ECH, with gastrointestinal or genitourinary cancer, and age ≥60 years. CONCLUSIONS: Patients with AF hospitalized with ECH may have a slightly elevated risk for future ischemic stroke. Particular consideration should be given to the optimal balance between the benefits and risks of anticoagulation therapy and the use of nonanticoagulant alternatives, such as left atrial appendage closure in this vulnerable population.
BACKGROUND AND PURPOSE: Anticoagulation therapy not only reduces the risk of ischemic stroke in atrial fibrillation (AF) but also predisposes patients to hemorrhagic complications. There is limited knowledge on the risk of first-ever ischemic stroke in patients with AF after extracranial hemorrhage (ECH). METHODS: We conducted a retrospective study using the California State Inpatient Database including all nonfederal hospital admissions in California from 2005 to 2011. The exposure variable was hospitalization with a diagnosis of ECH with a previous diagnosis of AF. The outcome variable was a subsequent hospitalization with acute ischemic stroke. We excluded patients with stroke before or at the time of ECH diagnosis. We calculated adjusted hazard ratios for ischemic stroke during follow-up and at 6-month intervals using Cox regression models adjusted for pertinent demographics and comorbidities. In subgroup analyses, subjects were stratified by primary ECH diagnosis, severity/type of ECH, age, CHA2DS2-VASc score, or the presence/absence of a gastrointestinal or genitourinary cancer. RESULTS: We identified 764 257 patients with AF (mean age 75 years, 49% women) without a documented history of stroke. Of these, 98 647 (13%) had an ECH-associated hospitalization, and 22 748 patients (3%) developed an ischemic stroke during the study period. Compared to patients without ECH, subjects with ECH had ≈15% higher rate of ischemic stroke (overall adjusted hazard ratio, 1.15 [95% CI, 1.11-1.19]). The risk appeared to remain elevated for at least 18 months after the index ECH. In subgroup analyses, the risk was highest in subjects with a primary admission diagnosis of ECH, severe ECH, gastrointestinal-type ECH, with gastrointestinal or genitourinary cancer, and age ≥60 years. CONCLUSIONS:Patients with AF hospitalized with ECH may have a slightly elevated risk for future ischemic stroke. Particular consideration should be given to the optimal balance between the benefits and risks of anticoagulation therapy and the use of nonanticoagulant alternatives, such as left atrial appendage closure in this vulnerable population.
Authors: Vanessa Roldán; Francisco Marín; Sergio Manzano-Fernández; Pilar Gallego; Juan Antonio Vílchez; Mariano Valdés; Vicente Vicente; Gregory Y H Lip Journal: J Am Coll Cardiol Date: 2013-09-18 Impact factor: 24.094
Authors: Andrew Cunningham; C Michael Stein; Cecilia P Chung; James R Daugherty; Walter E Smalley; Wayne A Ray Journal: Pharmacoepidemiol Drug Saf Date: 2011-03-08 Impact factor: 2.890
Authors: A García-Noblejas; S Osorio; A I Durán; R Córdoba; S Nistal; B Aguado; J Loscertales; N Gómez Journal: Haemophilia Date: 2005-05 Impact factor: 4.287
Authors: Steven V Manoukian; Frederick Feit; Roxana Mehran; Michele D Voeltz; Ramin Ebrahimi; Martial Hamon; George D Dangas; A Michael Lincoff; Harvey D White; Jeffrey W Moses; Spencer B King; E Magnus Ohman; Gregg W Stone Journal: J Am Coll Cardiol Date: 2007-03-09 Impact factor: 24.094
Authors: Robert W V Flynn; Thomas M MacDonald; Gordon D Murray; Ronald S MacWalter; Alexander S F Doney Journal: Stroke Date: 2010-10-14 Impact factor: 7.914
Authors: J'Neka S Claxton; Richard F MacLehose; Pamela L Lutsey; Faye L Norby; Lin Y Chen; Wesley T O'Neal; Alanna M Chamberlain; Lindsay G S Bengtson; Alvaro Alonso Journal: PLoS One Date: 2018-09-10 Impact factor: 3.240